Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Monopar Therapeutics Inc ( (MNPR) ) is now available.
On September 14, 2025, Monopar Therapeutics Inc. announced the presentation of new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 for Wilson disease at the 150th American Neurological Association Annual Meeting. The data, which pooled efficacy outcomes from three clinical trials and safety data from a fourth, highlighted sustained neurological improvement, crossover benefits, psychiatric outcomes, and a favorable safety profile, underscoring ALXN1840’s potential for treating both neurological and hepatic manifestations of Wilson disease.
The most recent analyst rating on (MNPR) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Monopar Therapeutics Inc stock, see the MNPR Stock Forecast page.
Spark’s Take on MNPR Stock
According to Spark, TipRanks’ AI Analyst, MNPR is a Neutral.
Monopar’s overall stock score is primarily affected by its financial performance challenges, such as negative cash flows and lack of revenue. However, the strong cash position and debt-free status provide some stability. The technical indicators show neutral market sentiment, while the new CFO appointment brings a positive strategic outlook. The valuation reflects typical biotech hurdles with a negative P/E ratio.
To see Spark’s full report on MNPR stock, click here.
More about Monopar Therapeutics Inc
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs. The company is working on late-stage ALXN1840 for Wilson disease and has radiopharmaceutical programs including MNPR-101-Zr for imaging advanced cancers and MNPR-101-Lu and MNPR-101-Ac225 for treating advanced cancers.
Average Trading Volume: 42,900
Technical Sentiment Signal: Buy
Current Market Cap: $303.7M
Learn more about MNPR stock on TipRanks’ Stock Analysis page.